Myeloproliferative Neoplasms

Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.

Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.

Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.

Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.

Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Gecacitinib, a dual JAK/ACVR1 inhibitor, showed spleen volume, symptom and anemia improvements in patients with myelofibrosis.

Idoroenyi Amanam, MD, discusses the efficacy of first-line luspatercept vs erythropoiesis-stimulating agents in real-world patients with lower-risk MDS.

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.

Rami Komrokji, MD, shares results from a pooled analysis of outcomes with imetelstat based on prior therapy in transfusion-dependent lower-risk MDS.

SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Venetoclax plus azacitidine did not yield an OS benefit vs placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes.

Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.

The FDA granted fast track designation to nuvisertib for intermediate- or high-risk myelofibrosis.

The EBMT have developed a machine learning model designed to identify and stratify transplant risk for patients with myelofibrosis.

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.

Durable improvements in transfusion independence and an early indication of potential OS benefit were seen with luspatercept in extended follow-up.